Pfizer pockets roughly £2.5B as it shaves off final stake in consumer health spinoff Haleon
After charting similar moves throughout 2024, Pfizer this week completed a sale of its remaining shares in Haleon, taking home around 2.5 billion pounds sterling ($3.2 billion) for its stake in the standalone consumer health giant. GSK, which owned a 13% stake in Haleon after the unit's 2022 demerger, sold the remainder of its position in the company last May.
After charting similar moves throughout 2024, Pfizer this week completed a sale of its remaining shares in Haleon, taking home around 2.5 billion pounds sterling ($3.2 billion) for its stake in the standalone consumer health giant. GSK, which owned a 13% stake in Haleon after the unit's 2022 demerger, sold the remainder of its position in the company last May.
